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ABSTRACT The calcium-binding protein S100A4 is a central mediator of metastasis forma-
tion in colon cancer. S100A4 is a target gene of the Wnt/β-catenin pathway, which is consti-
tutively active in the majority of colon cancers. In this study a high-throughput screen was 
performed to identify small-molecule compounds targeting the S100A4-promoter activity. In 
this screen calcimycin was identified as a transcriptional inhibitor of S100A4. In colon cancer 
cells calcimycin treatment reduced S100A4 mRNA and protein expression in a dose- and 
time-dependent manner. S100A4-induced cellular processes associated with metastasis for-
mation, such as cell migration and invasion, were inhibited by calcimycin in an S100A4-specif-
ic manner. Calcimycin reduced β-catenin mRNA and protein levels despite the expression of 
Δ45-mutated β-catenin. Consequently, calcimycin inhibited Wnt/β-catenin pathway activity 
and the expression of prominent β-catenin target genes such as S100A4, cyclin D1, c-myc, 
and dickkopf-1. Finally, calcimycin treatment of human colon cancer cells inhibited metastasis 
formation in xenografted immunodeficient mice. Our results demonstrate that targeting the 
expression of S100A4 with calcimycin provides a functional strategy to restrict cell motility in 
colon cancer cells. Therefore calcimycin may be useful for studying S100A4 biology, and 
these studies may serve as a lead for the development of treatments for colon cancer 
metastasis.
INTRODUCTION
S100A4 is a ubiquitous small, calcium-binding protein that enables 
cell migration and invasion to increase cell motility (Garrett et al., 
2006). Consequently, S100A4 expression is up-regulated during 
wound healing, neurite outgrowth, fibrosis, or neovascularization—
all physiological processes that rely on increased cell motility. How-
ever, overexpression of S100A4 is often correlated with pathological 
conditions such as epithelial–mesenchymal transition, tumor out-
growth, and metastasis formation (Schneider et al., 2008; Boye and 
Maelandsmo, 2010).
In colon cancer distant metastases are the major cause for cancer 
death, rendering this disease the second-most-frequent cause of 
cancer-related death in the Western world (Jemal et al., 2008). 
S100A4 expression is significantly associated with metastasis forma-
tion in colorectal cancer patients, and the expression of S100A4 rep-
resents a significant prognostic marker in colorectal carcinoma 
(Gongoll et al., 2002; Cho et al., 2005; Stein et al., 2006). Despite 
S100A4 increasing the metastatic potential of the cell, S100A4 
transgenic mice are not phenotypically changed (Ambartsumian 
et al., 1996). However, when these are crossed with spontaneous 
tumor-forming mice, S100A4 overexpression leads to highly 
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aggressive primary tumors and formation of metastasis (Davies 
et al., 1996). Highly metastatic mouse mammary carcinoma cells in-
jected into S100A4 null mice are unable to form metastases (Grum-
Schwensen et al., 2005). These observations suggest that S100A4 is 
not simply a marker for metastatic disease but rather has a causal 
role in mediating this process.
Tumor growth and metastasis depend on increased cell migra-
tion, invasion, and angiogenesis. S100A4 is involved in all of these 
processes by interaction with multiple proteins in the cytoplasm and 
extracellular space. For instance, intracellular S100A4 increases cell 
migration by rearranging proteins of the cytoskeleton. S100A4 binds 
tropomyosin and nonmuscle myosin II in a Ca2+-dependent manner 
and inhibits the actin-regulated ATPase activity of myosin II 
(Kriajevska et al., 1994; Ford et al., 1997). It thus promotes the disas-
sembly of myosin filaments and inhibits their reassembly (Ford et al., 
1997; Li et al., 2003). S100A4 is located at the leading edge of mi-
grating cells (Kim and Helfman, 2003), where it induces the formation 
of flexible protrusions. Moreover, in the presence of a chemoattrac-
tant, S100A4 enhances directed migration (Li and Bresnick, 2006). 
Thus the S100A4–myosin II interaction not only increases cell motil-
ity, but it also enhances cell polarization and directed migration.
S100A4 expression is associated with reduced expression levels 
of E-cadherin, thus loosening epithelial cell adhesion (Keirsebilck 
et al., 1998). In addition, S100A4 reduces cell adhesion by interacting 
with liprin-β1 (Kriajevska et al., 2002). S100A4 can access the extra-
cellular space by a yet-unknown mechanism, by which it interacts 
with endothelial-bound annexin II and thus enhances angiogenesis 
(Ambartsumian et al., 2001; Kriajevska et al., 2002). Extracellular 
S100A4 can also bind to the receptor for glycation end products and 
thereby activate matrix metalloproteinase-13 (MMP-13) expression 
(Yammani et al., 2006). Furthermore, up-regulation of MMP-2 and 
MMP-9 expression by extracellular S100A4 allows cell invasion and 
thus promotes metastasis formation (Mathisen et al., 2003; Saleem 
et al., 2006).
S100A4 gene transcription in colon cancer cells is regulated by 
the canonical Wnt/β-catenin pathway, one of the most frequently 
deregulated pathways in colon cancer (Stein et al., 2006). The path-
way strictly controls the cytoplasmic level of β-catenin via a destruc-
tion complex. In this complex β-catenin is phosphorylated and thus 
marked for proteasomal degradation (Barker and Clevers, 2006). 
Mutations within this pathway lead to intracellular accumulation of 
β-catenin, which then translocates to the nucleus and activates 
β-catenin/T cell factor (TCF) target gene transcription (Giles et al., 
2003; Stein et al., 2006).
Because S100A4 plays such a central role in the process of me-
tastasis formation, the inhibition of S100A4 expression provides a 
promising strategy for novel antimetastastic treatments (Sack and 
Stein, 2009). To identify potential S100A4 transcription inhibitors, 
we performed a high-throughput screen for compounds that inhib-
ited S100A4-promoter activity. Thus we identified calcimycin as a 
novel inhibitor of S100A4 transcription, which overcomes a constitu-
tively active Wnt/β-catenin pathway and significantly restricts 
S100A4-induced cell motility in colon cancer cells.
RESULTS
Identification of S100A4 transcription inhibitor calcimycin
Calcimycin was identified as an inhibitor for S100A4 expression in a 
high-throughput screen of the Library of Pharmacologically Active 
Compounds (LOPAC) 1280, a collection of 1280 pharmacologically 
active compounds that have shown effects on major drug target 
classes such as kinases, G proteins, and ion channels. HCT116/
S100A4pLUC cells expressing S100A4-promoter-driven firefly lu-
ciferase were exposed to 20 twofold dilutions of calcimycin. After 
24 h, luciferase activity was determined as a read-out for S100A4-
promoter activity (Figure 1A). From the high-throughput data it was 
found that calcimycin inhibited luciferase activity in a concentration-
dependent manner, with an EC50 of 2.7 μM (95% confidence interval 
[CI], 1.0–4.0 μM). At the same time growth inhibition was assessed 
from the high-throughput data, yielding an IC50 of ∼80 μM (95% CI, 
15.2–403.9 μM).
To define cytotoxic side effects potentially affecting further ex-
periments, the effect of calcimycin on cell viability of HCT116 cells 
was analyzed more precisely by manual pipetting. Exposure of 
HCT116 cells to calcimycin concentrations ranging from 2 nM to 
300 μM for 24 h resulted in a reduction of cell viability in a concen-
tration-dependent manner with an IC50 of 2.1 μM (95% CI, 
1.5–2.2 μM; Figure 1B).
We next analyzed the ability of calcimycin to reduce endogenous 
S100A4 expression in HCT116 cells. Exposure of HCT116 cells to 
increasing concentrations of calcimycin for 24 h resulted in a con-
centration-dependent reduction of S100A4 mRNA and protein. 
Treatment with 1 μM calcimycin reduced S100A4 expression to 30% 
of that for the solvent-treated control (Figure 1C). Cell viability was 
not affected by this concentration of calcimycin after 24 h. Therefore 
we chose the calcimycin concentration of 1 μM for use in the follow-
ing studies.
S100A4 expression is inhibited in a time-dependent manner 
by calcimycin
To assess the kinetics of the calcimycin effect, HCT116 cells were 
exposed to 1 μM calcimycin, and S100A4 expression was analyzed 
every 6 h. S100A4 mRNA was reduced in a time-dependent manner. 
After 12 h of treatment a basal reduction level of ∼30% of the solvent-
treated control was observed (Figure 1D). After 18 h of treatment the 
S100A4 protein levels were also reduced. S100A4 expression inhibi-
tion continued for 5 consecutive days after a single dose of 1 μM 
calcimycin (Figure 1E). Similar to HCT116 cells, HCT116/vector cells 
showed reduced S100A4 mRNA to ∼30% of solvent-treated control 
cells after 1 μM calcimycin treatment for 24 h (Figure 1F). In contrast, 
HCT116/S100A4 cells showed no significant reduction in S100A4 
mRNA or protein upon calcimycin treatment. These cells overex-
pressed S100A4 cDNA under the control of a cytomegalovirus (CMV) 
promoter, which was not targeted by calcimycin treatment.
S100A4-induced cell migration and invasion is inhibited 
by calcimycin
We previously showed that S100A4 expression in colon tumors sig-
nificantly correlates with metastasis formation (Stein et al., 2006). 
Moreover, S100A4 drives metastasis formation by increasing cell mi-
gration and invasion (Garrett et al., 2006). Therefore we next exam-
ined S100A4-induced cell motility in the presence of calcimycin. 
Exposure of HCT116 cells to calcimycin significantly reduced the 
number of migrated cells to 20% of that for solvent-treated HCT116 
cells (Figure 2A). Similarly, calcimycin treatment inhibited cell migra-
tion of HCT116/vector cells to 16% of that for the control cells. In 
contrast, HCT116/S100A4 cells showed no significant reduction in 
cell migration upon calcimycin treatment. Cell invasion of calcimy-
cin-treated HCT116 and HCT116/vector cells was inhibited to <30% 
of that for the solvent-treated control cells (Figure 2B). In contrast, 
cell invasion of HCT116/S100A4 cells was not significantly changed 
upon calcimycin treatment. Directed migration analyzed by wound-
healing assay revealed that calcimycin clearly inhibited wound clo-
sure in HCT116 and HCT116/vector cells but not in HCT116/S100A4 
cells (Figure 2C). In summary, calcimycin displayed an antimigratory 
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and anti-invasive effect in HCT116 cells, and this effect was over-
come by the exogenous overexpression of S100A4.
Calcimycin inhibits anchorage-dependent and 
anchorage-independent cell proliferation
We next analyzed cell proliferation under calcimycin treatment. Ex-
posure of HCT116, HCT116/vector, and HCT116/S100A4 cells to a 
single dose of 1 μM calcimycin resulted in a clear inhibition of an-
chorage-dependent proliferation after day 3 
(Figure 3A). Calcimycin further inhibited an-
chorage-independent growth as analyzed 
by colony formation. On exposure to calci-
mycin the number of colonies formed by 
HCT116, HCT116/vector, and HCT116/
S100A4 cells was significantly reduced to 
<5% of that for solvent-treated control cells 
(Figure 3B). Furthermore, as shown in the 
insets of the microphotographs, the size of 
colonies was clearly reduced by calcimycin 
treatment. Proliferation of cells that exoge-
nously overexpress S100A4 was also af-
fected by calcimycin treatment. Thus the 
antiproliferative effect of calcimycin on an-
chorage-dependent and anchorage-inde-
pendent growth was not overcome by an 
increased S100A4 expression level.
Calcimycin inhibits S100A4 expression, 
cell motility, and proliferation in other 
human colon cancer cell lines
We next analyzed calcimycin effects in other 
human colon cancer cell lines. Exposure of 
SW620, LS174T, and SW480 cells to 1 μM 
calcimycin for 24 h reduced the S100A4 
mRNA level to <40% of that for the respec-
tive solvent-treated controls (Figure 4A). 
S100A4 protein in these cells was clearly re-
duced upon calcimycin treatment. In DLD-1 
cells no S100A4 mRNA and protein expres-
sion was detected, and therefore no further 
effect by calcimycin was possible.
Exposure of SW620, LS174T, and SW480 
cells to 1 μM calcimycin for 24 h inhibited 
cell migration to <25% of that for the re-
spective solvent-treated controls (Figure 4B). 
DLD-1 cells presented the lowest migration 
rate, which was not further affected by calci-
mycin treatment. Cell invasion of SW620, 
LS174T, and SW480 cells was reduced to 
<30% of that for the respective solvent-
treated controls by calcimycin treatment 
(Figure 4C). The low cell invasion rate of 
DLD-1 cells was not significantly changed 
upon calcimycin treatment. In the wound-
healing assay solvent-treated SW620, 
LS174T, and SW480 cells were able to close 
the wound by day 4 after wound insertion 
(Figure 4D). In contrast, in solvent-treated 
DLD-1 cells wound closure was not com-
pleted by day 4, which was consistent with 
their decreased migration and invasion 
rates. Following a single dose of 1 μM calci-
mycin, wound closure, as measurement for directed migration, 
was impaired in all four colon cancer cell lines for 4 d post–wound 
insertion.
Anchorage-dependent cell proliferation was inhibited upon cal-
cimycin treatment in all four colon cancer cell lines as measured on 
day 4 (Figure 4E). In a colony formation assay solvent-treated 
SW620, LS174T, and SW480 cells formed large colonies by day 
7 (Figure 4F). Colony formation was inhibited in all four colon cancer 
FIgURE 1: S100A4-promoter activity is inhibited by calcimycin in a concentration- and time-
dependent manner. Luciferase activity and cell viability of calcimycin-treated HCT116/
S100A4pLUC cells were determined after 24 h. S100A4/G6PDH mRNA ratios were determined 
by qRT-PCR. S100A4 and GAPDH protein levels were measured by Western blot. (A) High-
throughput screening data of calcimycin inhibiting S100A4 promoter–driven reporter activity 
and cell viability. (B) Cell viability of HCT116 cells treated with increasing concentrations of 
calcimycin for 24 h is reduced in s concentration-dependent manner (C) S100A4 mRNA and 
protein levels are reduced in HCT116 cells treated with increasing concentrations of calcimycin. 
(C, D) S100A4 expression is reduced in HCT116 cells treated with a single dose of 1 μM 
calcimycin for the time indicated. Data represent mean ± SE (n = 4). Statistical significance was 
analyzed by two-sided ANOVA and Bonferroni post hoc multiple comparison test. (E) CMV 
promoter–driven S100A4 expression is not affected by calcimycin treatment. Data represent 
mean ± SE (n = 3). Statistical significance was analyzed by Student’s t test.
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cell lines following calcimycin treatment. Colonies of solvent-treated 
DLD-1 cells were smaller than colonies of other solvent-treated co-
lon cancer cells lines. However, the size of DLD-1 colonies was still 
reduced upon calcimycin treatment. Quantification of formed colo-
nies revealed that calcimycin treatment significantly reduced the 
number of colonies in all four colon cancer cell lines to <10% of the 
respective-solvent treated controls (Figure 4G). In summary, calci-
mycin inhibited cell migration and invasion of various colon cancer 
cell lines in relation to their S100A4 expression level. Cell prolifera-
tion was inhibited independent of the S100A4 expression level of 
S100A4 in these cells.
Calcimycin inhibits constitutively active Wnt/β-catenin 
pathway signaling
We previously reported that S100A4 is a β-catenin target gene (Stein 
et al., 2006). Therefore we investigated Wnt/β-catenin pathway ac-
tivity using the TOP/FOPflash reporter assay to assess the mecha-
nism underlying calcimycin inhibition of S100A4 expression. We 
used HCT116 cells that are heterozygous for mutated β-catenin. 
The mutated β-catenin lacks serine 45, the initial phosphorylation 
site needed for proteasomal degradation (Amit et al., 2002). Consis-
tent with this mutation, in these cells expression of the TOPflash 
reporter is increased. Treatment of HCT116 cells with calcimycin re-
duced the TOPflash reporter activity to <30% upon calcimycin treat-
ment (Figure 5A). In HAB68mut cells, which are homozygous for this 
β-catenin mutation, calcimycin treatment reduced TOPflash reporter 
activity to <10% of that for solvent-treated HCT116 cells. TOPflash 
reporter activity of solvent-treated HAB92wt cells, which are homozy-
gous for wild-type β-catenin, was <30% of the activity found in cells 
that bear a constitutively active Wnt/β-catenin pathway due to mu-
tated β-catenin. Moreover, calcimycin treatment of HAB92wt cells 
further reduced this TOPflash reporter activity to 12%.
We next analyzed the expression level of β-catenin, which repre-
sents the central player of this pathway. In calcimycin-treated 
HCT116, HAB68mut, and HAB92wt cells the β-catenin mRNA levels 
were reduced to <50% of that for solvent-treated HCT116 cells 
(Figure 5B). Consistent with this result, the β-catenin protein level 
was diminished upon calcimycin treatment of these cells.
Reduced β-catenin levels should result in reduced target gene 
transcription. Therefore we analyzed the expression levels of promi-
nent β-catenin/TCF target genes such as cyclin D1 (Shtutman et al., 
1999), c-myc (He et al., 1998), and dickkopf-1 (DKK-1; Gonzalez-
Sancho et al., 2005). In calcimycin-treated HCT116 cells the expres-
sion of cyclin D1, c-myc, and DKK-1 was inhibited to 35, 25, and 2% 
of the solvent-treated controls, respectively (Figure 5C).
We analyzed the effect of calcimycin on S100A4 expression in 
the presence of mutated or wild-type β-catenin and found that 
S100A4 mRNA was reduced to 35% in HAB68mut and HCT116 cells 
and was hardly detectable in HAB92wt cells (Figure 5D). In parallel, 
calcimycin treatment reduced S100A4 protein levels in HCT116 and 
HAB68mut cells, whereas no S100A4 protein was detectable in 
HAB92wt cells. Cell migration in HCT116 and HAB68mut cells was 
inhibited to the extent of HAB92wt cells, which was <25% of that for 
solvent-treated HCT116 cells (Figure 5E). These results provide evi-
dence that calcimycin restricts the Wnt/β-catenin pathway–driven 
S100A4 expression and thus S100A4-induced cell motility.
Calcimycin inhibits the metastatic potential of human colon 
cancer cells in xenografted mice
To test the effect of calcimycin on the ability of cells to form me-
tastasis in vivo, we used HCT116/LUC cells, which stably ex-
pressed the firefly luciferase protein and therefore allowed the 
FIgURE 2: S100A4 induced cell motility is inhibited by calcimycin. 
Cell migration was determined with Boyden chamber and wound-
healing assay. Cell invasion was measured with a Matrigel-covered 
Boyden chamber assay (A) Cell migration is inhibited in HCT116 and 
HCT116/vector cells but not in HCT116/S100A4 cells when treated 
with calcimycin. (B) Cell invasion is inhibited in calcimycin-treated 
HCT116 and HCT116/vector cells but not in HCT116/S100A4 cells. 
Data represent mean ± SE (n = 5). Statistical significance was analyzed 
with Student’s t test. (C) Directed migration is inhibited in calcimycin-
treated HCT116 and HCT116/vector cells but not in HCT116/S100A4 
cells. Microphotographs were taken with 10× magnification 4 d after 
wound was entered.
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From the reduced liver luminescence 
signal in mice of the calcimycin group, we 
hypothesized that the calcimycin treatment 
hampered HCT116/LUC cells from forming 
metastases in the liver tissue. We therefore 
performed immunohistological staining for 
human cytokeratin-19 in liver cryosections 
of mice injected with control and calcimycin-
treated cells. In the livers of control mice the 
incidence of micrometastases was clearly 
higher than in those of mice of the calcimy-
cin group (Figure 6D). Moreover, the size of 
the micrometastases was reduced in livers 
of mice injected with calcimycin-treated 
cells.
We next quantified the amount of hu-
man DNA in the liver sections of control and 
calcimycin mice by quantitative PCR amplifi-
cation of human satellite DNA as previously 
described (Becker et al., 2002). In livers from 
mice of the calcimycin group the amount of 
human DNA was reduced to ∼25% of that of 
control mice, indicating that the calcimycin 
treatment indeed inhibited human colon 
cancer cells from forming liver metastases 
(Figure 6E). Analysis of the human-specific 
S100A4 expression in liver metastases of the 
xenografted mice revealed that in livers 
from mice of the calcimycin group the 
S100A4 mRNA was hardly detectable, in 
contrast to the control mice (Figure 6F). 
From these data we conclude that the treat-
ment of colon cancer cells with calcimycin 
restricted their potential to form liver metas-
tases in vivo.
DISCUSSION
Intensive research has demonstrated the 
central role of S100A4 in the process of 
cancer metastasis, which qualifies S100A4 as a potentially promis-
ing target for therapeutic intervention against metastasis (Sherbet, 
2009; Boye and Maelandsmo, 2010). Most of the work concerning 
S100A4 has concentrated on the elucidation of the mechanism by 
which this molecule drives metastasis. Less work has focused on 
the inhibition of S100A4 to reduce S100A4-induced cell motility. 
Here we report the calcium ionophore calcimycin as an inhibitor of 
S100A4 transcription in colon cancer cells. We show that calcimy-
cin treatment inhibits a constitutively active Wnt/β-catenin path-
way, thereby inhibiting S100A4 expression and leading to re-
stricted S100A4-induced cell migration and invasion in vitro and 
in vivo.
In a high-throughput screen we identified calcimycin as one of 
the most effective inhibitors of S100A4-promoter activity. In this 
screen we used HCT116 cells in which the S100A4-promoter was 
highly active. Inhibition of S100A4-promoter activity by calcimy-
cin indicated that calcimycin targets S100A4 at the transcription 
level. Calcimycin reduced S100A4 mRNA levels in a concentra-
tion- and time-dependent manner in colon cancer cell lines with 
increased basal S100A4 expression levels. In line with our obser-
vation in human colon cancer cells, calcimycin has been reported 
to reduce the S100A4 mRNA level in mouse mammary adenocar-
cinoma cells, as well as in human monocytes and lymphocytes 
detection of metastases via noninvasive in vivo luminescence 
imaging. Cells were treated with 1 μM calcimycin or solvent for 
24 h and subsequently inoculated intrasplenically into nonobese 
diabetic/severe immune-deficient (NOD/SCID)–IL2R− mice. Six 
days posttransplantation, luminescence signals were detected in 
the lateral and ventral abdominal cavity, where the spleen and 
liver are situated, respectively (Figure 6A). In control mice, the 
ventral luminescence signal was stronger than in mice from the 
calcimycin group.
To investigate the origin of luminescence, the spleen and the 
liver were dissected. All animals developed tumors in the spleen, 
which were clearly visible in the bright-field analysis (Figure 6B). A 
strong luminescence signal originated from the spleen tumor, indi-
cating that the tumor was formed by HCT116/LUC cells. Bright-field 
analysis of the resected livers revealed no clear differences between 
mice of the control and calcimycin groups. However, the lumines-
cence signal from livers of control mice was clearly stronger than 
that from livers of calcimycin mice.
Quantification of the luminescence signal revealed no significant 
differences in the signal intensity of spleen tumors from mice of the 
control and calcimycin groups (Figure 6C). In contrast, the lumines-
cence signal of livers was reduced to 30% in mice of the calcimycin 
group compared with control mice.
FIgURE 3: Calcimycin inhibits anchorage-dependent and anchorage-independent cell growth. 
Anchorage-dependent growth was determined by MTT assay; anchorage-independent growth 
was measured in a soft-agar colony formation assay. (A) Anchorage-dependent cell proliferation 
of HCT116, HCT116/vector, and HCT116/S100A4 cells was reduced upon calcimycin treatment 
(, solvent-treated HCT116; , calcimycin-treated HCT116; , solvent-treated HCT116/vector; , 
calcimycin-treated HCT116/vector; , solvent-treated HCT116/S100A4; , calcimycin-treated 
HCT116/S100A4 cells). (B) Anchorage-independent cell proliferation of HCT116, HCT116/vector, 
and HCT116/S100A4 cells was inhibited by calcimycin. Number of colonies was counted on day 
7, when microphotographs were taken with 10× and 40× (insets) magnification. Data represent 
mean ± SE (n = 3). Statistical significance was determined by Student’s t test.
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(Grigorian et al., 1994). We further showed that S100A4 protein 
levels were also suppressed in a concentration- and time-depen-
dent manner following calcimycin treatment in several colon can-
cer cell lines.
Calcimycin is an ionophorous, polyether 
antibiotic isolated from Streptomyces char-
treusensis. Calcimycin facilitates the trans-
port of divalent cations across the mem-
brane, which makes it a useful tool to study 
calcium signaling (Pressman, 1976). Because 
calcimycin elevates intracellular calcium lev-
els (Gwak et al., 2006), one would expect 
that calcimycin treatment would increase 
S100A4 protein activity, which depends on 
calcium ions (Santamaria-Kisiel et al., 2006). 
However, in our study, we did not see an in-
creased migratory or invasive phenotype in 
exogenously S100A4-overexpressing cells 
that were treated with calcimycin. Although 
we cannot completely exclude that calcimy-
cin caused increased S100A4 protein activ-
ity, we definitely show here that reducing the 
overall expression level of S100A4 signifi-
cantly inhibits S100A4-induced cell motility.
S100A4 protein drives metastasis by in-
teraction with a multitude of partner pro-
teins, leading to increased cell migration and 
invasion (Belot et al., 2002; Stein et al., 2006). 
Consequently, down-regulation of S100A4 
expression by calcimycin restricted cell mi-
gration in colon cancer cells. This is in line 
with observations from RNA interference ex-
periments in which knockdown of S100A4 
mRNA was shown to reduce cell migration 
(Gao et al., 2005; Tabata et al., 2009). Of in-
terest, calcimycin was not able to suppress 
cell migration or invasion in cells that exog-
enously overexpressed S100A4. From these 
observations we conclude that the antimi-
gratory and anti-invasive effect of calcimycin 
was caused by the down-regulation of 
S100A4 expression from its native promoter.
Knockdown of S100A4 mRNA levels with 
short hairpin RNA (shRNA) was shown to in-
hibit cell proliferation in vitro and to reduce 
tumor growth and metastasis in vivo (Shi 
et al., 2006). Moreover, in gastric cancer 
cells, shRNA knockdown of S100A4 in-
creased the occurrence of apoptosis (Hua 
et al., 2009). In our study, knockdown of 
S100A4 expression by treatment with calci-
mycin was accompanied by reduced cell 
proliferation. Exogenous overexpression of 
S100A4 was ineffective in overcoming the 
antiproliferative effect of calcimycin, which 
suggests that this effect is independent of 
the S100A4 expression level.
S100A4 is a target gene of the Wnt/β-
catenin pathway (Stein et al., 2006). We 
found that calcimycin treatment inhibits 
β-catenin transcription, which leads to the 
inhibition of the Wnt/β-catenin pathway ac-
tivity in colon cancer cells and explains its inhibitory effect on S100A4 
expression. Of interest, calcimycin was able to overcome a constitu-
tively active Wnt/β-catenin pathway, since it reduced β-catenin also 
in cells that are heterozygous or even homozygous for Δ45-mutated 
FIgURE 4: Calcimycin inhibits S100A4 expression, cell motility, and proliferation in human colon 
cancer cell lines. S100A4/G6PDH mRNA ratios were determined by qRT-PCR. S100A4 and 
GAPDH protein levels were measured by Western blot. Cell migration was determined with 
Boyden chamber and wound-healing assay. Cell invasion was measured with a Matrigel-covered 
Boyden chamber assay. Anchorage-dependent growth was determined by MTT assay; 
anchorage-independent growth was measured in a soft-agar colony formation assay. (A) S100A4 
expression was reduced upon calcimycin treatment. (B) Calcimycin treatment inhibited cell 
migration. (C) Cell invasion was inhibited upon calcimycin treatment. (D) Calcimycin inhibited 
directed migration. (E) Calcimycin inhibited cell proliferation. (F, G) Calcimycin reduced the size 
and number of colonies formed, respectively. Number of colonies was counted on day 7, when 
microphotographs were taken with 10× and 40× (insets) magnification. Data represent mean ± 
SE (n = 3). Statistical significance was determined by Student’s t test.
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β-catenin. In line with our findings, calcimycin treatment also abol-
ished Wnt/β-catenin pathway activity in HEK293 cells that stably 
expressed the TOPflash reporter plasmid (Gwak et al., 2006).
In line with reduced Wnt/β-catenin pathway activity, we found 
that S100A4 and other β-catenin/TCF target genes such as cyclin D1, 
c-myc, and DKK-1 were down-regulated following calcimycin treat-
ment. Cyclin D1 and c-myc are known oncogenes, and their overex-
pression causes increased cell proliferation (He et al., 1998; Shtutman 
et al., 1999). Knockdown of β-catenin expression levels by shRNA 
was shown to result in reduced levels of cyclin D1 and c-myc, and this 
reduction was associated with reduced cell proliferation (Huang et 
al., 2007). Consistent with this observation, in our study calcimycin 
reduced the cyclin D1 and c-myc mRNA levels, which might explain 
the observed inhibition of anchorage-dependent and anchorage-in-
dependent cell proliferation following calcimycin treatment.
Intrasplenic inoculation of S100A4 overexpressing cells was 
shown to induce liver metastases in xenografted mice (Stein et al., 
2006). Because S100A4 is a major regulator of colon cancer metas-
tasis, its inhibition should result in restricted metastasis formation. 
Indeed, we found in this study that calcimycin treatment of human 
colon cancer cells restricted their potential to form liver metastases 
in vivo. The number and size of liver metastases formed by calcimy-
cin treated cells were significantly reduced. Bioluminescence imag-
ing, as well as immunohistochemistry, visualized larger and more 
frequent micrometastases in livers of control animals than in livers of 
mice from the calcimycin group. The amount of human satellite 
DNA was reduced in livers of calcimycin mice, supporting the obser-
vation that fewer human colon cancer cells invaded the liver tissue. 
Thus calcimycin treatment restricted the metastatic potential of co-
lon cancer cells in vivo.
We are aware that by interfering with the Wnt/β-catenin pathway, 
calcimycin will have several different functions and actions within the 
cell. Among these functions we show that calcimycin inhibits S100A4 
expression and that this inhibition leads to reduced cell motility. We 
showed that HCT116/S100A4 cells migrated and invaded despite 
the calcimycin treatment. The inhibitory effect of calcimycin on cell 
migration and invasion was overcome by exogenous overexpres-
sion of S100A4. Thus we provide evidence that the antimigratory 
and anti-invasive effect of calcimycin was specific to the calcimycin-
mediated S100A4 expression inhibition.
In conclusion, our study reports calcimycin as a novel inhibitor of 
S100A4-promoter activity, which leads to reduced S100A4 expression 
and thus impairs S100A4-induced cell motility and metastasis. Be-
cause metastasis is the major cause of colon cancer death, there is an 
urgent need for antimetastatic treatment. S100A4, as a mediator of 
this disease progression, provides a promising therapeutic target. We 
provide evidence that targeting S100A4 expression by application of 
calcimycin restricts S100A4-induced cell migration and invasion in 
vitro and in vivo. Therefore we show that calcimycin is a useful com-
pound not only to study S100A4 biology, but also to form the basis 
for the development of treatments against colon cancer metastasis.
MATERIALS AND METHODS
Cell lines and treatments
The human colon cancer cell line HCT116 and its derivatives 
HAB-68mut and HAB-92wt were kindly provided by Todd Waldman 
(Georgetown University, Washington, DC). HCT116 cells are heterozy-
gous for gain-of-function mutated Δ45-β-catenin. In HAB-68mut and 
HAB-92wt the wild-type or mutated allele of β-catenin was deleted, 
respectively, by homologous recombination (Kim et al., 2002). These 
cell lines were expanded briefly in culture and cryopreserved in mul-
tiple replicate vials. The cell banks were tested by PCR and culture 
methods and found to be free of mycoplasma. To authenticate the 
HAB-68mut and HAB-92wt cell lines as HCT116 derivatives, short tan-
dem repeat (STR) genotyping was performed in August 2010 using 
the ABI Identifier Kit (Life Technologies, Darmstadt, Germany). The 
STR genotypes were consistent with published genotypes for 
HCT116. All cells were tested for the correct β-catenin genotype by 
restriction fragment length polymorphism as previously described 
(Stein et al., 2006). Cells were cultured in RPMI-1640 medium supple-
mented with 10% fetal calf serum (PAA Laboratories, Pasching, Aus-
tria) in a humidified incubator at 37°C and 5% CO2. HCT116 cells 
were transfected to express S100A4-promoter controlled firefly lu-
ciferase (HCT116/S100A4pLUC cells), CMV promoter–controlled 
firefly luciferase (HCT116/LUC), CMV promoter–controlled S100A4 
cDNA (HCT116/S100A4 cells), or the empty vector as control 
(HCT116/vector cells). The S100A4 promoter was a kind gift from 
FIgURE 5: Calcimycin inhibits constitutively active Wnt/β-catenin 
pathway. Activity of the Wnt/β-catenin pathway was analyzed by TOP/
FOPflash reporter assay. Quantification of mRNA was performed with 
qRT-PCR; protein expression was determined by Western blot. 
(A) Wnt/β-catenin pathway was reduced in calcimycin-treated HCT116 
cells and in derivative cell lines HAB68mut and HAB92wt. (B) The 
expression of β-catenin mRNA and protein was reduced in calcimycin-
treated in HCT116, HAB68mut, and HAB92wt cells. (C) mRNA levels of 
β-catenin/TCF transcription target genes cyclin D1, c-myc, and DKK-1 
were reduced upon calcimycin treatment. (D) S100A4 expression was 
inhibited in HCT116, HAB68mut, and HAB92wt cells treated with 
calcimycin. (E) Cell migration of HCT116, HAB68mut, and HAB92wt cells 
was decreased upon calcimycin treatment. Data represent mean ± SE 
(n = 3). Statistical significance was analyzed by Student’s t test.
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start master mix (Roche) was used. Cyclin D1 and c-myc cDNAs 
were quantified with SYBR green (Roche). For quantification of the 
housekeeping gene glucose-6-phosphate dehydrogenase (G6PDH) 
cDNA the hG6PDH Roche Kit (Roche) was used.
Western blot was performed with the following antibodies: a 
polyclonal rabbit anti–human S100A4 antibody (Dako, Glostrup, 
Denmark), a polyclonal goat anti–human glycerin-aldehyde-
3-phosphate dehydrogenase (GAPDH) antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA), and a monoclonal mouse 
anti–human β-catenin antibody. Immunoblotting for GAPDH 
served as loading control.
Immunohistochemistry was performed as previously described 
(Stein et al., 2011). Briefly, cryosections were stained with rabbit 
anti–human-specific cytokeratin-19 antibody (dilution 1:50; Acris 
Antibodies, Herford, Germany) and horseradish peroxi-
dase–coupled anti-rabbit antibody (dilution 1:1000; Promega, 
Madison, WI).
Cell migration, cell invasion, and wound-healing assay
For the Boyden chamber assay (Boyden, 1962), 2.5 × 105 cells were 
seeded into transwell filter membrane chambers (pore size, 12.0 μm; 
Millipore, Billerica, MA) and allowed to accommodate for 15 h. Cells 
were treated with 1 μM calcimycin for 18 h. The number of cells that 
migrated to the lower chamber was counted in a Neubauer cham-
ber. For the invasion assays, transwell membranes were coated with 
1:3 diluted Matrigel (BD Biosciences, Heidelberg, Germany). For 
the wound-healing assay, 2.5 × 105 cells were seeded at 60% conflu-
ence 24 h before a wound of ∼300 μM width was made with a pi-
pette tip. Medium was exchanged daily, and microphotographs 
were taken on day 4.
David Allard (University of Exeter and Plymouth, Exeter, United King-
dom) and comprised the sequence from −1487 to +33 base pairs 
around the S100A4 transcription start site (Hernan et al., 2003). The 
S100A4 cDNA was kindly provided by Claus Heizmann (University of 
Zurich, Zurich, Switzerland; Engelkamp et al., 1992).
Substances from the LOPAC 1280 and additional samples of cal-
cimycin (both Sigma-Aldrich, St. Louis, MO) were dissolved in dim-
ethylsulfoxide. Dilutions were performed with RPMI-1640 medium.
High-throughput screening and cell cytotoxicity assay
A BIOMEK2000 automatic pipetting system (Beckman Coulter, 
Brea, CA) was used to seed 2.5 × 103 HCT116/S100A4pLUC cells/
well into 384-well plates. Cells were exposed to dilutions of each 
compound of the LOPAC 1280 for 24 h. Luciferase expression was 
determined using Britelite reagent in a Wallac Victor reader (both 
PerkinElmer, Waltham, MA). In parallel, cell cytotoxicity of the com-
pounds was measured by Alamar blue cytotoxicity assay. Briefly, af-
ter 24 h of incubation with cells, plates were treated with Alamar 
blue (Sigma-Aldrich) solution for 4 h and then read on a fluores-
cence plate reader at excitation and emission wavelengths of 530 
and 590 nm, respectively. Compounds showing inhibition in the 
S100A4 promoter screen were counterscreened using an HIF-1 pro-
moter screen to establish selective activity (Rapisarda et al., 2002).
Quantitative real-time PCR, Western blot analysis, 
and immunohistochemistry
Quantitative real-time (qRT) PCR was carried out using the LightCy-
cler480 (Roche, Mannheim, Germany) as described previously (Stein 
et al., 2006) with the primers and probes summarized in Table 1. For 
β-catenin, S100A4, and DKK-1 cDNA quantification HybProbe Fast-
gene Primer/probe Sequence 5′–3′
β-Catenin Forward primer gtg cta tct gtc tgc tct agt a
Reverse primer ctt cct gtt tag ttg cag cat c
FITC probe agg act tca cct gac aga tcc aag tca-FITC
Lcred640-probe LCRed640-cgt ctt gtt cag aac tgt ctt tgg act ctc-phosphate
Cyclin D1 Forward primer ctg ttt ggc gtt tcc cag agt cat c
Reverse primer agc ctc ctc ctc aca cct cct c
c-myc Forward primer acc ctt gcc gca tcc acg aaa c
Reverse primer cgt agt cga ggt cat agt tcc tgt tgg
DKK-1 Forward primer tag cac ctt gga tgg gta ttc
Reverse primer ata ttt cta gtc cat gag agc c
FITC probe gtc tcc ggt cat cag act gtg cc-FITC
Lcred640 probe LCRed640-agg att gtg ttg tgc tag aca ctt ctg g-phosphate
S100A4 Forward primer ctc agc gct tct tct ttc
Reverse primer ggg tca gca gct cct tta
FITC probe tgt gat ggt gtc cac ctt cca caa gt-FITC
Lcred640 probe LCred640-tcg ggc aaa gag ggt gac aag t-phosphate
Human satellite DNA Forward primer ggg ata att tca gct gac taa aca g
Reverse primer aaa cgt cca ctt gca gat tct ag
FITC probe ctt cac ata aaa act aca cag atg cat tct cag g-FITC
LCRed640 probe LCred640-ctt ttt ggt gat gtt tgt att caa ctc cca g-phosphate
FITC, fluorescein isothiocyanate.
TAbLE 1: Primers and probes used for qRT-PCR.
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FIgURE 6: Calcimycin reduces the metastatic potential of human colon cancer cells in xenografted mice. Mice were 
intrasplenically injected with calcimycin- or solvent-treated HCT116/LUC cells. Two representative mice per group are 
shown. (A) Bioluminescence was measured 6 d posttransplantation in the region of spleen and liver (metastases target 
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organ). (B) Spleen tumor and liver metastases are visualized by bioluminescence imaging. (C) No significant difference in 
the luminescence signal of spleen tumors was found between mice injected with control or calcimycin-treated cells. The 
liver luminescence signal was significantly reduced in the calcimycin group. Data represent mean ± SE (n = 6). Statistical 
significance was analyzed by Student’s t test. (D) Immunohistochemistry for human cytokeratin-19 identified smaller and 
fewer micrometastases in the calcimycin group. (E) The amount of human satellite DNA was reduced in livers from the 
calcimycin group. (F) The S100A4 mRNA expression normalized to hG6PDH was absent in livers of mice of the 
calcimycin group. Data represent mean ± SE (n > 3). Statistical significance was analyzed by Student’s t test.
culated by sigmoidal dose–response curve fit of × = log(x) trans-
formed data. IC50 and EC50 values were given as geometric means 
with 95% confidence interval. All significance tests were two-sided. 
p < 0.05 was defined as statistically significant.
Cell proliferation and colony formation assay
For determination of cell proliferation, 8 × 103 cells were treated 
daily for 4 d with 1 μM calcimycin. For determination of viable 
cells 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT; Sigma-Aldrich) was added to a final concentration of 
0.5 mg/ml, incubated for 3 h, and dissolved by 10% SDS in 10 mM 
HCl. The optical density was measured at 560 nm. For colony forma-
tion assays 1 × 103 cells were resuspended in 1 μM calcimycin- or 
solvent-containing medium supplemented with 0.33% (wt/vol) aga-
rose and seeded as single cells. After incubation in a humidified in-
cubator at 37°C and 5% CO2 for 7 d, colonies were analyzed by light 
microscopy. Colonies were counted if they consisted of more than 
three cells.
TOP/FOPflash reporter assay
Transfection of 8 × 105 cells with TOPflash or FOPflash plasmids 
(Promega) occurred 24 h before the cells were treated with 1 μM 
calcimycin. After 18 h of treatment luciferase activity was measured 
by the Steady Glow Luciferase Assay System (Promega). TOPflash 
reporter gene expression (representing the Wnt/β-catenin pathway 
activity) was normalized to FOPflash reporter gene expression (rep-
resenting basal reporter gene expression).
In vivo bioluminescence imaging of xenograft mice
All experiments were performed in accordance with the United 
Kingdom Coordinating Committee for Cancer Research guidelines 
and approved by the State Office of Health and Social Affairs, 
Berlin, Germany. HCT116/LUC cells were treated with 1 μM calcimy-
cin or solvent 24 h before 2 × 106 cells were intrasplenically injected 
into eight NOD/SCID-IL2R− mice per group. Mice were anesthe-
tized by intraperitoneal injection of 35 mg/kg Hypnomidate (Jassen-
Cilag, Neuss, Germany) and received 150 mg/kg d-luciferin (Bio-
synth, Staad, Switzerland) intraperitoneally for bioluminescence 
imaging. Imaging was performed with the NightOWL LB 981 sys-
tem (Berthold Technologies, Bad Wildbad, Germany). ImageJ, ver-
sion 2.3, was used for color coding of signal intensity (presenting a 
256 grayscale) and for quantification of the luminescence signal. 
Mice were killed 6 d posttransplantation, when a clear liver signal 
was detected. The spleen (the tumor implantation site) and the liver 
(the metastasis target organ) were shock frozen in liquid nitrogen, 
and cryosections were performed for isolation of genomic DNA 
(Qiagen, Hilden, Germany) and mRNA (Roboklon, Berlin, Germany) 
and for immunohistochemistry.
Statistical analysis
Statistical analyses were performed with GraphPad Prism, version 
4.01. Comparison of two groups was done by Student’s t test. Com-
parison of a control versus several treated groups was performed by 
one-way analysis of variance (ANOVA) and Bonferroni post hoc mul-
tiple comparison. The inhibiting concentration 50 (IC50) was defined 
as the concentration that reduced cell viability to 50% of solvent-
treated control cells. The effective concentration 50 (EC50) was de-
fined to be the concentration at which reporter activity was reduced 
to 50% of solvent-treated control cells. The IC50 and EC50 were cal-
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